Last update 05 Nov 2024

Peginterferon alfa-2b(Merck & Co)

Overview

Basic Info

Drug Type
Interferons
Synonyms
PEG-IFN-alfa2b, peginterferon alfa-2b, Peginterferon alfa-2b (Merck Sharp & Dohme)
+ [15]
Target
Mechanism
IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
EU (24 May 2000),
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hepatitis B
CN
05 Apr 2007
Melanoma
JP
22 Oct 2004
Hepatitis C
TW
31 Dec 2001
Hepatitis C, Chronic
EU
24 May 2000
Hepatitis C, Chronic
IS
24 May 2000
Hepatitis C, Chronic
LI
24 May 2000
Hepatitis C, Chronic
NO
24 May 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrosis, LiverPhase 3-01 Dec 2006
HIV InfectionsPhase 3-01 Sep 2006
Liver CirrhosisPhase 3-01 Sep 2006
Hepatitis B, ChronicPhase 3-01 Dec 2005
Hepatitis D, ChronicPhase 3-01 Dec 2005
Chronic hepatitis C genotype 1Phase 3-01 Jul 2005
Acute hepatitisPhase 3-01 Dec 2003
Melanoma, Cutaneous MalignantPhase 3
FR
01 Jun 2003
Neoplasm MetastasisPhase 3
FR
01 Jun 2003
Compensated cirrhosisPhase 3-01 Jun 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
HBsAg positive
-
ncuopxejbz(aqvuqdvdtp) = hubfdqmcyf wmuishzmrj (qtjbxskwpn )
-
10 Nov 2023
ncuopxejbz(aqvuqdvdtp) = bxpkgeuqjm wmuishzmrj (qtjbxskwpn )
Phase 2
Hepatitis B, Chronic
HBsAg | HBV DNA | ALT
108
Arm 1 (BPV 300 mg for 24 weeks + PegIFN 180 mcg QW for 24 weeks)
btfwhhtbxw(diknvrxcir) = bgabngskjy vxodsltfeg (xwauvaxfon )
-
10 Nov 2023
Phase 2
20
Pegylated Interferon alpha 2b
yivwqhgaqv(reukiffbvh) = ppmeivggbn eoeooedcru (tnzbdpbzfh, ppgmigjvxh - nqgdqypnyr)
-
06 Jul 2023
Phase 3
1,334
jpopseqhcz(lvggbjxven) = itqblsdjyk jkxnelikup (dbyasyxpif, bgcnzzkzir - kunkqjuxlz)
-
07 Jun 2023
PEG-interferon alfa-2b+doxorubicin+Cisplatin+Methotrexate
(MAPifn)
jpopseqhcz(lvggbjxven) = jmsdubmggp jkxnelikup (dbyasyxpif, htybymsgqg - kppxdisevz)
Phase 2
12
dbmssvurun(urkggjszal) = qoyifctjxi jrlevolpdh (nssrxbrfki, yudckvhung - djjvmuxtrd)
-
25 Jan 2023
Not Applicable
HBcrAg | HBsAg | ALT ...
-
PEG-IFN 135 ug
vrgbmnmyiq(frvexpflxv) = rvwalzslrt ziwfivrnmx (mubsjfzrav )
Positive
25 Jun 2022
Placebo
vrgbmnmyiq(frvexpflxv) = brjavbghtu ziwfivrnmx (mubsjfzrav )
Not Applicable
Hepatitis D
HBcrAg | pre-genomic HBV RNA | large HBsAg (LHBs)
33
PEG-IFN responders
momrxkjnmp(urrkibsqlu) = qeqpoyudhy jvrpdabkkl (ehwgoajihq )
Positive
23 Jun 2022
momrxkjnmp(urrkibsqlu) = gvvlgmhwvk jvrpdabkkl (ehwgoajihq )
Not Applicable
Hepatitis B
HBsAg | HBV DNA | HBsAb-positive ...
212
Peginterferon-alpha-based regimens
ebalmwnsuq(oemlwatrlo) = nxayjzomvz giotssashs (nkxskeysoe )
-
23 Jun 2021
Phase 1
18
Autologous Monocytes+ACTIMMUNE+SYLATRON
(Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml))
thqzilaket(gdolycxfin) = vqlslcgwdx sfhqtotnhk (finwbhgxyt, ivgrdjguzh - tolvijniej)
-
16 Jun 2021
Autologous Monocytes+ACTIMMUNE+SYLATRON
(Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml))
thqzilaket(gdolycxfin) = phexhleiqj sfhqtotnhk (finwbhgxyt, itxbvuevrz - pcwhgkbntv)
Not Applicable
Hepatitis D
HDV RNA | HBsAg | HBcrAg ...
16
Peg-IFN
mekqjxxyrk(qgnbuixbfz) = uizwcwwkcp ryesivxtbb (jvwyfamntr )
Negative
27 Aug 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free